These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 29843776)

  • 1. Fatigue independently predicts different work disability dimensions in etanercept-treated rheumatoid arthritis and ankylosing spondylitis patients.
    Druce KL; Aikman L; Dilleen M; Burden A; Szczypa P; Basu N
    Arthritis Res Ther; 2018 May; 20(1):96. PubMed ID: 29843776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of presenteeism, absenteeism and job loss in patients commencing methotrexate or biologic therapy for rheumatoid arthritis.
    Gwinnutt JM; Leggett S; Lunt M; Barton A; Hyrich KL; Walker-Bone K; Verstappen SMM;
    Rheumatology (Oxford); 2020 Oct; 59(10):2908-2919. PubMed ID: 32097471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contextual factors influence work outcomes in employed patients with ankylosing spondylitis starting etanercept: 2-year results from AS@Work.
    Boonen A; Boone C; Albert A; Mielants H
    Rheumatology (Oxford); 2018 May; 57(5):791-797. PubMed ID: 29373701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity.
    Smolen JS; Strand V; Koenig AS; Szumski A; Kotak S; Jones TV
    Arthritis Res Ther; 2016 May; 18(1):114. PubMed ID: 27209012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of etanercept on work and activity impairment in employed moderate to severe rheumatoid arthritis patients in the United States.
    Hone D; Cheng A; Watson C; Huang B; Bitman B; Huang XY; Gandra SR
    Arthritis Care Res (Hoboken); 2013 Oct; 65(10):1564-72. PubMed ID: 23554320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fatigue contributes to work productivity impairment in patients with axial spondyloarthritis: a cross-sectional UK study.
    Espahbodi S; Bassett P; Cavill C; Freeth M; Hole J; Sengupta R
    Clin Exp Rheumatol; 2017; 35(4):571-578. PubMed ID: 28240589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with golimumab or infliximab reduces health resource utilization and increases work productivity in patients with ankylosing spondylitis in the QUO-VADIS study, a large, prospective real-life cohort.
    Claudepierre P; Van den Bosch F; Sarzi-Puttini P; Vastesaeger N; Govoni M; Kachroo S
    Int J Rheum Dis; 2019 Jun; 22(6):995-1001. PubMed ID: 30989813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with absenteeism, presenteeism and activity impairment in patients in the first years of RA.
    Bansback N; Zhang W; Walsh D; Kiely P; Williams R; Guh D; Anis A; Young A
    Rheumatology (Oxford); 2012 Feb; 51(2):375-84. PubMed ID: 22179728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis.
    García-Lagunar MH; Gutiérrez-Cívicos MR; García-Simón MS; Conesa-Zamora P; Jimenez-Santos E; Cano-Vivar P; García-Márquez A; Muñoz-García I; Viney AC
    Ann Pharmacother; 2017 May; 51(5):388-393. PubMed ID: 27920336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL.
    Fafá BP; Louzada-Junior P; Titton DC; Zandonade E; Ranza R; Laurindo I; Peçanha P; Ranzolin A; Hayata AL; Duarte A; Silveira IG; Costa I; Macieira JC; Guedes-Barbosa LS; Bertolo MB; Sauma MF; Silva MB; Freire M; Scheinberg MA; Fernandes V; Bianchi W; Miranda JR; Pinheiro GR; Carvalho HM; Brenol CV; Pereira IA; de Castro GR; de Morais JC; Oliveira SK; de Abreu MM; Toledo RA; Pinheiro MM; Vieira WP; Valim V;
    Clin Rheumatol; 2015 May; 34(5):921-7. PubMed ID: 25851594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis.
    Rudwaleit M; Mørup MF; Humphries B; Zannat NE; Willems D; Taieb V; Boonen A
    RMD Open; 2023 Nov; 9(4):. PubMed ID: 38035757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rheumatoid arthritis and work: The impact of rheumatoid arthritis on absenteeism and presenteeism.
    Verstappen SM
    Best Pract Res Clin Rheumatol; 2015 Jun; 29(3):495-511. PubMed ID: 26612244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Burden of rheumatoid arthritis on patients' work productivity and quality of life.
    Xavier RM; Zerbini CAF; Pollak DF; Morales-Torres JLA; Chalem P; Restrepo JFM; Duhau JA; Amado JR; Abello M; de la Vega MC; Dávila AP; Biegun PM; Arruda MS; Ramos-Remus C
    Adv Rheumatol; 2019 Nov; 59(1):47. PubMed ID: 31706348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Productivity loss of Japanese patients with rheumatoid arthritis - A cross-sectional survey.
    Sruamsiri R; Mahlich J; Tanaka E; Yamanaka H
    Mod Rheumatol; 2018 May; 28(3):482-489. PubMed ID: 28849715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
    Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
    Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying Persons with Axial Spondyloarthritis At Risk of Poor Work Outcome: Results from the British Society for Rheumatology Biologics Register.
    Macfarlane GJ; Shim J; Jones GT; Walker-Bone K; Pathan E; Dean LE
    J Rheumatol; 2019 Feb; 46(2):145-152. PubMed ID: 30385702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of 1-year anti-TNF-α therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis.
    Végh E; Kerekes G; Pusztai A; Hamar A; Szamosi S; Váncsa A; Bodoki L; Pogácsás L; Balázs F; Hodosi K; Domján A; Szántó S; Nagy Z; Szekanecz Z; Szűcs G
    Rheumatol Int; 2020 Mar; 40(3):427-436. PubMed ID: 31848735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic impact of adalimumab treatment in Japanese patients with rheumatoid arthritis from the adalimumab non-interventional trial for up-verified effects and utility (ANOUVEAU) study.
    Tanaka Y; Yamazaki K; Nakajima R; Komatsu S; Igarashi A; Tango T; Takeuchi T
    Mod Rheumatol; 2018 Jan; 28(1):39-47. PubMed ID: 28704126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
    Gonnet-Gracia C; Barnetche T; Richez C; Blanco P; Dehais J; Schaeverbeke T
    Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review of studies of productivity loss due to rheumatoid arthritis.
    Burton W; Morrison A; Maclean R; Ruderman E
    Occup Med (Lond); 2006 Jan; 56(1):18-27. PubMed ID: 16286432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.